Dr. David P. Warshal
Claim this profileCooper Hospital University Medical Center
Studies Esophageal Cancer
Studies Ovarian Cancer
15 reported clinical trials
33 drugs studied
Area of expertise
1Esophageal Cancer
Stage IV
Stage III
Stage II
2Ovarian Cancer
Stage IV
BRCA1 positive
Stage III
Affiliated Hospitals
Clinical Trials David P. Warshal is currently running
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting2 awards Phase 3
Lorigerlimab
for Ovarian Cancer
Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 60 participants will be enrolled. The study will assess the efficacy and safety of lorigerlimab in participants with PROC or CCGC. Participants will receive lorigerlimab by intravenous (IV) infusion on Day 1 of every 21-day treatment cycle. Treatment cycles will continue until progression of cancer, unacceptable side effects, withdrawal of consent by the participant, or the study ends. Participants will be monitored closely for side effects by physical exam and routine laboratory tests every cycle. Tumor status will be checked approximately every 9 weeks for the first year, then every 12 weeks for the duration of treatment. Participants will have a safety followup performed within 30 days after treatment discontinuation. Participants who discontinue study treatment for reasons other than progression of cancer, will continue CA-125 and tumor assessments every 12 weeks. Participants who discontinue study treatment for progression of cancer will enter the 6-month survival follow up portion of the study.
Recruiting1 award Phase 27 criteria
More about David P. Warshal
Clinical Trial Related2 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments David P. Warshal has experience with
- Carboplatin
- Paclitaxel
- Pembrolizumab
- Levonorgestrel-Releasing Intrauterine System
- Everolimus
- Mirvetuximab Soravtansine
Breakdown of trials David P. Warshal has run
Esophageal Cancer
Ovarian Cancer
Breast Cancer
Endometrioid Adenocarcinoma
Endometrial Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does David P. Warshal specialize in?
Is David P. Warshal currently recruiting for clinical trials?
Are there any treatments that David P. Warshal has studied deeply?
What is the best way to schedule an appointment with David P. Warshal?
What is the office address of David P. Warshal?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.